CICC's research report projects that United Imaging Healthcare is poised to generate revenue of RMB 13.821 billion in 2025, marking a significant 34.18% year-on-year surge. Meanwhile, the net profit attributable to shareholders is anticipated to climb to RMB 1.888 billion, reflecting a robust 49.60% year-on-year growth. The revenue figures have surpassed expectations, propelled by robust sales of high-end products and the swift expansion of overseas operations. However, profits have fallen slightly short of forecasts, mainly attributable to expenses that exceeded initial estimates. The resurgence in procurement activities has spurred vigorous revenue growth, while profits continue on a steady upward trajectory. It is essential to monitor the expected profit enhancements stemming from the introduction of high-end products and ultrasound product lines. Utilizing the DCF model (with a WACC of 7.1% and a perpetual growth rate of 2.0%), the target price is maintained at RMB 170, indicating a promising 33% upside potential. Consequently, the 'Outperform Industry' rating is reaffirmed.